ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more
ATAI Life Sciences BV (ATAI) - Net Assets
Latest net assets as of September 2025: $159.91 Million USD
Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has net assets worth $159.91 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($239.82 Million) and total liabilities ($79.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $159.91 Million |
| % of Total Assets | 66.68% |
| Annual Growth Rate | 14.28% |
| 5-Year Change | 22.21% |
| 10-Year Change | N/A |
| Growth Volatility | 130.6 |
ATAI Life Sciences BV - Net Assets Trend (2019–2024)
This chart illustrates how ATAI Life Sciences BV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ATAI Life Sciences BV (2019–2024)
The table below shows the annual net assets of ATAI Life Sciences BV from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $116.55 Million | -52.29% |
| 2023-12-31 | $244.32 Million | -8.07% |
| 2022-12-31 | $265.77 Million | -31.14% |
| 2021-12-31 | $385.96 Million | +304.70% |
| 2020-12-31 | $95.37 Million | +59.53% |
| 2019-12-31 | $59.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ATAI Life Sciences BV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68074500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.79 Million | 16.15% |
| Other Comprehensive Income | $-18.47 Million | -15.88% |
| Other Components | $816.18 Million | 701.81% |
| Total Equity | $116.30 Million | 100.00% |
ATAI Life Sciences BV Competitors by Market Cap
The table below lists competitors of ATAI Life Sciences BV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinochem International Corp
SHG:600500
|
$1.10 Billion |
|
ManpowerGroup Inc
NYSE:MAN
|
$1.10 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
$1.10 Billion |
|
DAEHAN SHIPBUILDING LTD
KO:439260
|
$1.10 Billion |
|
Energix - Renewable Energies Ltd.
PINK:ENREF
|
$1.10 Billion |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
$1.10 Billion |
|
Shenzhen Agricultural Products Co Ltd
SHE:000061
|
$1.10 Billion |
|
Österreichische Post AG
XETRA:O3P
|
$1.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ATAI Life Sciences BV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 242,962,000 to 116,297,000, a change of -126,665,000 (-52.1%).
- Net loss of 149,269,000 reduced equity.
- Other comprehensive income increased equity by 994,000.
- Other factors increased equity by 21,610,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-149.27 Million | -128.35% |
| Other Comprehensive Income | $994.00K | +0.85% |
| Other Changes | $21.61 Million | +18.58% |
| Total Change | $- | -52.13% |
Book Value vs Market Value Analysis
This analysis compares ATAI Life Sciences BV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.48x to 5.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.39 | $3.65 | x |
| 2020-12-31 | $0.60 | $3.65 | x |
| 2021-12-31 | $2.35 | $3.65 | x |
| 2022-12-31 | $1.67 | $3.65 | x |
| 2023-12-31 | $1.53 | $3.65 | x |
| 2024-12-31 | $0.73 | $3.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ATAI Life Sciences BV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -128.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -48463.96%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-128.35%) is below the historical average (-76.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -24.06% | 0.00% | 0.00x | 1.06x | $-20.01 Million |
| 2020 | -187.01% | -854.34% | 0.18x | 1.23x | $-178.93 Million |
| 2021 | -44.52% | -823.56% | 0.05x | 1.10x | $-205.50 Million |
| 2022 | -58.44% | -65401.29% | 0.00x | 1.17x | $-178.46 Million |
| 2023 | -16.56% | -12810.19% | 0.00x | 1.21x | $-64.52 Million |
| 2024 | -128.35% | -48463.96% | 0.00x | 1.37x | $-160.90 Million |
Industry Comparison
This section compares ATAI Life Sciences BV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ATAI Life Sciences BV (ATAI) | $159.91 Million | -24.06% | 0.50x | $1.10 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |